胰岛素样生长因子-Ⅱ和胰岛素样生长因子结合蛋白-1对妊娠早期胚胎发育的影响

目的 探讨胰岛素样生长因子-Ⅱ（insulin-like growth factorⅡ，IGF-Ⅱ）与胰岛素样生长因子结合蛋白1（insulin-like growth factor binding protein-1，IGFBP-1）在妊娠早期对胚胎发育的影响。方法 应用逆转录聚合酶链反应（RT—PCR）、酶联免疫吸附试验（ELISA）分别检测2002-04—2004-01中山大学附属一院47例早孕空胚妊娠妇女（观察组）和38例正常早孕人流妇女（对照组）绒毛组织中的IGF-Ⅱ、蜕膜组织IGFBP-1的mRNA表达量，及母血清中IGFBP-1水平，比较两组数值的相关性。结果 观察组蜕膜组织IGFBP．1mRNA为（3．30±0．32）mg／L，绒毛组织IGF-Ⅱ mRNA为（1．50±0．41）mg／L，母血清IGFBP-1为（50．87±12．08）μg／L；对照组蜕膜组织IGFBP-1 mRNA为（2．14±0．21）mg／L，绒毛组织IGF-Ⅱ mRNA为（3．80±0．17）mg／L，母血清IGFBP-1为（24．31±3．61）μg／L。观察组与对照组间IGF-Ⅱ mRNA、IGFBP-1 mRNA及母血清IGFBP-1比较差异有统计学意义（P〈0．05）；绒毛组织中IGF-Ⅱ mRNA与蜕膜组织中IGFBP-1 mRNA的表达量呈负相关，蜕膜组织IGFBP-1 mRNA与母血清IGFBP-1呈正相关：结论 IGF-Ⅱ、IGFBP-1可能可以作为早期胚胎发育预测潜能的指标，     

胰岛素样生长因子1及胰岛素样生长因子结合蛋白1表达与妊娠期高血压疾病发病的关系

目的探讨胰岛素样生长因子1(IGF-1)与胰岛素样生长因子结合蛋白1(IGFBP-1)在妊娠期高血压疾病发病中的作用。方法采用酶联免疫吸附法(ELISA)及免疫组化方法检测60例妊娠期高血压疾病患者(妊娠期高血压疾病组,其中妊娠期高血压20例、轻度子痫前期19例、重度子痫前期21例)及18例正常妊娠妇女(对照组)的血清及胎盘组织中IGF-1及IGFBP-1的水平,并分析妊娠期高血压疾病组患者血清中IGF-1水平与胎盘组织中IGFBP-1的相关性。结果(1)血清IGF-1水平:妊娠期高血压疾病组为(229±100)μg/L,明显低于对照组的(336±120)μg/L,两组比较,差异有统计学意义(P<0.01)。妊娠期高血压患者血清中IGF-1水平为(303±80)μg/L,轻度子痫前期患者为(233±77)μg/L,重度子痫前期患者为(155±73)μg/L。3者间比较,差异有统计学意义(P<0.05)。(2)胎盘组织中IGF-1阳性率:妊娠期高血压疾病组为48%(29/60),明显低于对照组的83%(15/18),两组比较,差异有统计学意义(P<0.01);轻、重度子痫前期患者明显低于对照组(P<0.05,P<0.01)。(3)血清中IGFBP-1水平:妊娠期高血压疾病组为(161±90)μg/L,明显高于对照组的(98±75)μg/L,两组比较,差异有统计学意义(P<0.01)。妊娠期高血压患者为(97±73)μg/L,轻度子痫前期患者为(157±69)μg/L,重度子痫前期患者为(225±81)μg/L。3者间比较,差异有统计学意义(P<0.05)。(4)胎盘组织中IGFBP-1阳性率:妊娠期高血压疾病组为77%(46/60),明显高于对照组的39%(5/18),两组比较,差异有统计学意义(P<0.01);轻、重度子痫前期患者明显高于对照组(P<0.05,P<0.01)。(5)相关性:妊娠期高血压疾病组患者血清及胎盘组织中IGF-1水平分别与相应部位的IGFBP-1水平均呈负相关(r=-0.269,P<0.05;r=-0.396,P<0.01)。血清中IGFBP-1水平与胎盘组织中IGFBP-1表达水平呈正相关(r=0.388,P<0.01)。结论孕妇血清及胎盘组织中IGF-1、IGFBP-1水平变化与妊娠期高血压疾病发病及病情发展有关。     

胰岛素样生长因子-Ⅰ及内皮素-1与胎儿生长受限的关系

目的探讨胰岛素样生长因子-Ⅰ(IGF-Ⅰ)及内皮素(ET-1)与胎儿生长受限(FGR)发病的关系。方法2001-06-2004-12中山市人民医院应用放射免疫分析法和酶联免疫吸附试验,分别测定42例FGR患儿脐静脉血、孕妇(FGR孕妇组)血清及羊水中IGF-Ⅰ和ET-1水平,并与同期住院的正常晚期妊娠妇女44例(正常孕妇组)作为对照。结果FGR组孕妇血清IGF-Ⅰ为(112·16±7·02)μg/L,低于正常妊娠组的(207·27±8·25)μg/L,差异有非常显著性意义,P<0·01;FGR组脐血清IGF-Ⅰ为(16·27±7·38)μg/L,低于正常组的(44·89±6·44)μg/L,差异有非常显著性意义,P<0·01;FGR组羊水中IGF-Ⅰ与正常妊娠组差异无显著意义,P>0·05;孕妇血清、脐血清IGF-Ⅰ与新生儿出生体重呈正相关。FGR组脐血ET-1为(79·34±3·67)ng/L,高于正常妊娠组的(43·96±4·16)ng/L,差异有非常显著性意义,P<0·01;FGR组羊水IGF-Ⅰ为(21·96±1·89)ng/L,高于正常组的(10·41±2·13)ng/L,差异有非常显著性意义,P<0·01;而FGR组孕妇血清中IGF-Ⅰ与正常妊娠组差异无显著性意义,P>0·05;孕妇羊水、脐血清ET-1与新生儿出生体重呈负相关。结论IGF-Ⅰ及ET-1在FGR的发病中可能起到非常重要的作用。     

胰岛素样生长因子与胎儿出生体质量的关系

目的:探讨孕妇和新生儿血清胰岛素、胰岛素样生长因子Ⅰ(IGF-Ⅰ)、IGF-Ⅱ、胰岛素样生长因子结合蛋白1(IGFBP-1)、IGFBP-3与胎儿出生体质量的关系,探究胎儿生长发育的影响因子。方法:选择2012年1月—2013年2月杭州市第一人民医院住院分娩的孕妇230例,根据胎儿出生体质量与胎龄关系的分类诊断标准将胎儿出生体质量水平分为3组:小于胎龄儿(SGA)组15例,适于胎龄儿(AGA)组162例,大于胎龄儿(LGA)组53例。采用酶联免疫吸附法集中测定孕妇血清、新生儿脐血血清胰岛素、IGF-Ⅰ、IGF-Ⅱ、IGFBP-1和IGFBP-3水平。结果:3组孕妇血清和新生儿脐血血清胰岛素、IGF-Ⅰ、IGF-Ⅱ、IGFBP-3水平差异有统计学意义(均P0.001),LGA组大于AGA组,AGA组大于SGA组(均P0.01),母血血清IGF-Ⅱ和脐血血清胰岛素、IGF-Ⅰ、IGF-Ⅱ水平为胎儿出生体质量水平的影响因素。结论:母血血清IGF-Ⅱ和脐血血清胰岛素、IGF-Ⅰ、IGF-Ⅱ可能是影响胎儿生长发育的关键因子。     

类胰岛素生长因子与胎儿生长发育关系的研究

目的 探讨类胰岛类生长因子（insulin-like growth factor-1,IGF-1)与胎儿生长发育的关系。方法 对38例正常儿、20例母体糖尿病新生和15例巨大儿的足月分娩前母及脐血进行IGF－1测定,明确IGF－1与新生儿体重和身长的关系。结果 正常足月分娩的脐血IGF－1值平均为70μg/L,脐血IGF－1和新生儿体重和身长均呈正相关。母血IGF－1是脐血IGF－1的2．87倍,母血IGF－1和脐血IGF－1呈明显正相关。糖尿病组母血和脐血的IGF－1均高于正常组,巨大儿组的母血IGF－1高于正常组。结论 IGF－1是促进胎儿生长发育的一种细胞因子。孕期母血IGF－1监测可以预测胎儿生长发育情况。     

胰岛素样生长因子1和胰岛素促胎儿生长作用探讨

胰岛素等是调节胎儿生长的重要激素 ,近来胰岛素样生长因子对胎儿的促生长作用愈来愈受到重视 [1 ,2 ] 。本研究通过对 6 4例新生儿脐血清胰岛素样生长因子 1(IGF- 1)和胰岛素的检测 ,探讨 IGF-1和胰岛素在胎儿生长中的作用 ,分析影响 IGF- 1水平的相关因素。一、对象和方法1.研究对象 :6 4例新生儿 ,男 2 5例 ,女 39例 ,胎龄 2 9～ 42周 ,体重 130 0～410 0 g。适于胎龄 (AGA)儿 43例 ,小于胎龄 (SGA)儿 15例 ,大于胎龄 (L GA)儿 6例。2 .方法 :新生儿出生时采集脐血 4ml,测量胎盘重量、新生儿体重 ,身长和孕母身高。采用放免法测…     

胰岛素样生长因子及胰岛素样生长因子结合蛋白-3与胎儿生长受限的关系

目的　探讨胰岛素样生长因子 (IGF) Ⅰ、IGF Ⅱ和IGF结合蛋白 3(IGFBP 3)与胎儿生长的关系 ,以及IGF在胎儿生长受限 (FGR)发病中的作用。方法　选取 2 0例分娩FGR胎儿 (FGR组 )、10例分娩巨大儿 (巨大儿组 )及 2 0例分娩正常儿 (对照组 )的产妇 ,抽取 3组产妇分娩后肘静脉血及其新生儿脐静脉血 ,分离血清。采用放射免疫法和免疫放射法测定 3组产妇及其新生儿血清中IGF Ⅰ、IGF Ⅱ及IGFBP 3的水平。结果　 (1)FGR组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为(130 5± 2 6 0 ) μg/L、(2 40± 0 42 ) μg/L及(5 5 79± 848) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 6± 1 7) μg/L、(1 5 4± 0 31) μg/L及 (86 9± 183) μg/L。 (2 )巨大儿组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (30 9 7± 44 6 ) μg/L、(2 43± 0 2 5 ) μg/L及(5 5 6 2± 742 ) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 9 6± 2 3 9) μg/L、(2 19± 0 2 9) μg/L及(16 82± 130 )μg/L。(3)对照组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (30 7 9± 70 7) μg/L、(2 41± 0 36 )μg/L及 (5 5 86± 6 78) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 8 9     

脐血GH、IGF-Ⅰ、IGFBP-3水平与特发性胎儿生长受限的关系

目的:探讨生长激素(GH)、胰岛素样生长因子-Ⅰ(IGF-Ⅰ)、胰岛素样生长因子结合蛋白-3(IGFBP-3)与特发性胎儿生长受限(FGR)的关系.方法:采用巢式病例对照的研究设计方法,使用放射免疫分析法,检测42例FGR患者(特发性FGR组)和42例适于胎龄儿(正常对照组)脐血清中GH、IGF-Ⅰ、IGFBP-3水平,通过配对设计差值t检验、Pearson相关分析对实验结果进行统计分析.结果:①特发性FGR组GH水平高于正常对照组(P<0.01);特发性FGR组脐血IGF-Ⅰ、IGFBP-3水平均明显低于正常对照组(P<0.01);特发性FGR组脐血IGF-Ⅰ/IGFBP-3的比值低于正常对照组(P<0.01);②脐血GH水平与出生体重负相关(r=-0.443,P=0.000),脐血IGF-Ⅰ、IGFBP-3水平与出生体重正相关(r=0.497,P=0.000;r=0.331,P=0.000);脐血GH水平与IGF-Ⅰ水平负相关(r=-0.290,P=0.000),脐血IGF-Ⅰ水平与IGFBP-3水平正相关(r=0.245,P=0.024).结论:GH、IGF-Ⅰ及IGFBP-3可能参与胎儿生长发育过程,是特发性胎儿生长受限发生的重要影响因素.     

IGF-1、IGF-2、IGFBP-3与非糖尿病孕妇巨大儿发生的相关性研究

目的探讨胰岛素样生长因子1、2（IGF-1、IGF-2）、胰岛素样生长因子结合蛋白3（IGFBP-3）与非糖尿病孕妇巨大儿发生的关联性。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩的初产妇,孕期纵向观察,抽取妊娠中期（26～28周）和妊娠足月（38～41周）的母血及孕妇分娩时新生儿出生体重≥4000g30例（巨大儿组）、2500～3500g30例（正常组）的脐血,应用放射免疫法检测IGF-1、IGF-2、IGFBP-3的水平,并进行对比分析。结果①两组孕妇妊娠足月IGF-1水平均高于妊娠中期,差异有高度统计学意义（分别为P〈0.0001、P〈0.001）,但妊娠中期和足月时,巨大儿组与正常组二组间比较差异均无统计学意义（P〉0.05）。巨大儿组脐血IGF-1水平高于正常组,差异有高度统计学意义（P〈0.0001）;②孕妇血清IGF-2水平巨大儿组与正常组比较差异无统计学意义（P〉0.05）;③孕妇妊娠中期、妊娠足月血清IG-FBP-3水平巨大儿组明显高于正常组,差异有高度统计学意义（分别为P〈0.001、P〈0.01）;④母血IGFBP-3水平、脐血IGF-1水平与新生儿出生体重正相关。结论 IGF-1参与了胎儿生长发育的调节;胎儿自身循环中的IGF-1与新生儿出生体重有关;非糖尿病孕妇血清IGFBP-3水平与巨大儿形成有关。     

胰岛素样生长因子 -Ⅰ与胎儿出生体重的关系

目的了解胰岛素样生长因子Ⅰ（ＩＧＦⅠ）在胎儿生长发育中所起的作用。方法选择１７１例产妇及其所分娩的新生儿１６４例，根据出生体重将新生儿分为大于胎龄儿（ＬＧＡ）组：产妇７７例、新生儿６４例；适于胎龄儿（ＡＧＡ）组：产妇５９例、新生儿５９例；小于胎龄儿（ＳＧＡ）组：产妇３５例、新生儿４３例。用放射免疫法测定血清中ＩＧＦⅠ的浓度。结果母血中ＩＧＦⅠ浓度均高于脐血，两者间存在浓度梯度（Ｐ＜０．０１）；母、脐血中ＩＧＦⅠ浓度随孕周增加，至３９～４０周达顶峰；３３～４０周间除ＳＧＡ组外，血中ＩＧＦⅠ浓度与新生儿出生体重呈正相关（ｒ＝０．９１～０．９８）；ＳＧＡ组母、脐血ＩＧＦⅠ浓度与ＡＧＡ组相比，均有不同程度降低（Ｐ＜０．０１）。结论母、儿的ＩＧＦⅠ分泌系统相对独立。ＩＧＦⅠ是调节胎儿生长发育的重要生长因子之一。     

Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism

Objective: To study the insulin-like growth factor-1 (IGF-1) axis in hirsute women.

Design: Controlled clinical study.

Setting: Tertiary care institutional hospital.

Patient(s): Forty hirsute women and 17 women with normal menstrual cycles.

Intervention(s): Basal and ACTH-stimulated samples were obtained, and sampling was repeated 1 (gonadal stimulation) and 21 (gonadal suppression) days after a single 3.75-mg IM dose of triptorelin. Controls did not receive triptorelin for ethical reasons.

Main Outcome Measure(s): Serum GH, IGF-1, IGF-binding protein-3 (IGFBP-3), insulin, glucose, total testosterone, sex hormone-binding globulin, E₂, and gonadotropin levels. Basal and ACTH-stimulated steroid precursors were measured.

Result(s): Patients with idiopathic hirsutism were identified by normal serum androgen levels (n = 17). Those with functional ovarian hyperandrogenism (n = 15) were identified by an increase in the serum testosterone level that normalized during gonadal suppression, whereas those with functional adrenal hyperandrogenism (n = 8) were identified by an initial increase in the testosterone level that persisted during gonadal suppression. The adrenal hyperandrogenism group had increased IGF-1 levels compared with the control, idiopathic hirsutism, and ovarian hyperandrogenism groups. Patients with ovarian hyperandrogenism had normal IGF-1 concentrations, but their IGFBP-3 concentrations were lower than those of controls. No differences were observed in GH levels between any of the groups. These results persisted when the influence of age was corrected for.

Conclusion(s): The IGF-1 axis appears to be involved in the pathogenesis of hyperandrogenism, especially in patients with adrenal hyperandrogenism, who have a clear increase in IGF-1 levels. Moreover, patients with ovarian hirsutism have decreased IGFBP-3 concentrations, which might enhance IGF-1 bioavailability.     

Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia.

OBJECTIVES: To investigate whether the serum concentrations of insulin, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein-1 (IGFBP-1) were altered in women with mild pre-eclampsia, severe pre-eclampsia, and eclampsia. METHODS: In this prospective study, we investigated 20 mild pre-eclamptic, 20 severe pre-eclamptic, and 20 eclamptic patients in the third trimester. The control group consisted of 20 healthy pregnant women. Serum levels of insulin, IGF-1, and IGFBP-1 were measured. RESULTS: In patients with eclampsia, serum levels of IGF-1 were lower, and IGFBP-1 were higher, respectively, than control and other study groups (P<0.001) The values of IGF-1 in mild pre-eclampsia and severe pre-eclampsia were lower compared with control groups (both P<0.01), but there were no differences between mild and severe pre-eclampsia. The serum levels of IGFBP-1 in severe pre-eclampsia were higher compared with control groups (P<0.01), but there was no statistical difference between mild pre-eclampsia and other groups. CONCLUSIONS: IGF-1 was lower, and IGFBP-1 was higher in pre-eclamptic and eclamptic patients than controls, these alterations were related to the severity of pre-eclampsia.     

Maternal zinc and cord blood zinc, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 levels in small-for-gestational-age newborns

PURPOSE: To determine the relationship between maternal serum zinc (Zn) levels and birth weight of the offspring and their correlation with cord blood Zn, insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels. METHOD: 22 term small-for-gestational-age (SGA) and 34 term appropriate-for-gestational-age (AGA) infants and their mothers were included. Maternal and cord blood Zn levels and cord blood IGF-1 and IGFBP-3 levels were measured. RESULTS: Eighteen percent of mothers had Zn deficiency (< 75 mcg/dl). No significant difference between IGF-1 and IGFBP-3 levels and birth weight of infants of the mothers with and without Zn deficiency was found. Maternal and neonatal Zn levels correlated (r = 0.38, p < 0.01). Mean IGF-1 and IGFBP-3 levels were significantly lower in the SGA group compared to the AGA group (42.3 +/- 16.8 ng/ml, 1.2 +/- 0.2 mcg/ml, and 62.4 +/- 22.7 ng/ml, 1.5 +/- 0.4 mcg/ml, p < 0.001). A correlation was found between birth weight, IGF-1 and IGFBP-3 levels, and weight gain of the mother during pregnancy (p < 0.01). CONCLUSIONS: Zn deficiency was not observed to be a risk factor for low birth weight. The significant difference between the SGA and AGA babies' IGF-1 and IGFBP-3 levels emphasizes function of the IGF system in intrauterine growth.     

IGF-1及IGFBP-3在子宫内膜癌组织中的表达及意义

目的:探讨胰岛素样生长因子-1( IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)在子宫内膜癌组织中的表达及临床意义.方法:38例子宫内膜癌患者为实验组,30例因子宫肌瘤手术患者(术后病理证实正常子宫内膜组织)为对照组.采用酶联免疫吸附法检测血清IGF-1及IGFBP-3水平,应用荧光PCR法检测IGF-1及IGFBP-3在内膜组织中基因及其产物表达.结果:子宫内膜癌组织IGF-1 mRNA(2.106±4.943)表达水平高于对照组(0.388±0.501),两者差异有统计学意义(P＜0.05);而IGFBP-3 mRNA (0.690±0.564)表达水平低于对照组(1.306±1.393),两者差异有统计学意义(P＜0.05).实验组中IGF-1 (76.958±95.600μg/L)在血清的表达水平高于对照组(28.474±11.744 μg/L),实验组IGFBP-3血清表达水平(27.260±13.284 μg/L)低于对照组(47.650±25.979 μg/L),差异均有统计学意义(P ＜0.05).结论: IGF-1、IGFBP-3与子宫内膜癌发生有关.检测血清IGF-1、IGFBP-3有助于发现子宫内膜癌高危人群,探索是否可作为其筛查及预后判断指标.     

Maternal serum insulin-like growth factor (IGF-I) and binding proteins IGFBP-1 and IGFBP-3 at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates

Objective

To investigate the possible value of maternal serum concentration of insulin-like growth factor-I (IGF-I), IGF binding protein-1 (IGFBP-1) and IGFBP-3 at 11–13 weeks’ gestation in the prediction of small-for-gestational age (SGA) neonates.

Study design

Maternal serum concentrations of IGF-I, IGFBP-1 and IGFBP-3 at 11–13 weeks were measured in 60 cases that subsequently delivered SGA neonates in the absence of pre-eclampsia, and compared to 120 non-SGA controls.

Results

In the SGA group, compared to the non-SGA group, there was significantly lower median IGF-I (61.8, IQR 43.4–93.4 ng/mL vs 94.9, IQR 56.7–131.2 ng/mL, p = 0.002) and IGFBP-1 (58.2, IGR 39.8–84.9 ng/mL vs 81.4, IGR 57.3–105.5 ng/mL, p = 0.002) but not IGFBP-3 (54.5, IGR 45.6–61.5 ng/mL vs 55.4, IGR 47.4–64.9 ng/mL, p = 0.402). However, after multiple regression analysis and adjustment for maternal characteristics, these biomarkers were not useful in predicting SGA.

Conclusion

Maternal serum IGF-I, IGFBP-1 and IGFBP-3 at 11–13 weeks are unlikely to be useful biochemical markers for early prediction of SGA.     

胰岛素样生长因子Ⅰ及胰岛素与胎儿宫内发育迟缓发病的关系

目的 探讨胰岛素样生长因子１（ＩＧＦ－Ｉ）及胰岛素与胎儿宫内发育迟缓（ＩＵＧＲ）发病的关系。方法 应用放射免疫分析法和酶联免疫吸附试验,分别测定１７例ＩＵＧＲ患儿,孕妇（ＩＵＧＲ组）血清及羊水中Ｉｎｓ和ＩＧＦ－Ｉ水平,同期住院的正常晚期妊娠妇女３８例（正常妊娠组）作为对照。     

IUGR脐血中表皮生长因子水平的研究

目的：从内分泌因素的角度对胎儿生长发育及其异常进行研究，以探讨ＩＵＧＲ与脐血中表皮生长因子（ＥＧＦ）水平的关系。方法：选择伴有ＩＵＧＲ的孕妇２２例及正常孕妇３８例，于分娩时抽取脐血，用放射免疫测定法（ＲＩＡ）测定ＥＧＦ水平，同时测定胎儿体重与胎盘重量，比较两组的差异。结果：正常体重儿（３４０９．１±２８４．７９ｇ）组的脐血ＥＧＦ水平（６２４．６４±７３．９０μｇ／Ｌ）明显高于低体重儿（２４０３．３±２７７．４１ｇ）组（２１７．９０±５４．５２μｇ／Ｌ）（Ｐ＜０．０５）；ＩＵＧＲ组胎盘重量３５４．３±９２．６４ｇ亦明显低于正常组的５４２．１±７８．３２ｇ（Ｐ＜０．０１）。结论：脐血中低ＥＧＦ水平是ＩＵＧＲ的相关因素之一，对妊娠过程中ＥＧＦ的作用及其机制进行研究有助于探讨ＩＵＧＲ病因及临床治疗。